Will Pierre Fabre and Array Have Best-In-Class MEK/BRAF Inhibitor?
Executive Summary
Updated results from the COLUMBUS trial in BRAF-mutant advanced melanoma presented at ASCO revealed stellar overall survival data for the combination of encorafenib and binimetinib. Rivals Novartis and Roche will have noted that approval in the US is expected before the end of June.